Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 30, Number 12—December 2024
Research Letter

Canine Multidrug-Resistant Pseudomonas aeruginosa Cases Linked to Human Artificial Tears–Related Outbreak

Author affiliation: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (E.R. Price), New Jersey Department of Health, Trenton, New Jersey, USA (E.R. Price, D. McDermott, A. Sherman, L. Kelley, J. Mehr, R. Greeley), University of Pennsylvania School of Veterinary Medicine, Philadelphia, Pennsylvania, USA (S.D. Cole)

Suggested citation for this article

Abstract

We report 2 canine cases of carbapenemase-producing Pseudomonas aeruginosa within a United States veterinary hospital associated with a human outbreak linked to over-the-counter artificial tears. We investigated veterinary hospital transmission. Veterinary antimicrobial resistance surveillance and infection prevention and control enhancements are needed to reduce transmission of carbapenemase-producing organisms.

Carbapenem antimicrobial drugs are reserved for highly resistant gram-negative bacterial infections. Carbapenemase enzymes, which hydrolyze and inactivate carbapenems, are commonly encoded on mobile genetic elements that can spread among bacterial genera and species and amplify resistance. Therefore, carbapenemase-producing organisms (CPOs) are a major public health concern (1). Although less commonly documented compared with humans, CPOs have been identified in companion animals and suspected transmission reported between humans and animals (24).

In March and June 2023, New Jersey Department of Health (NJDOH) was notified of carbapenemase-producing Pseudomonas aeruginosa (CP-PsA) isolated from 2 separately owned pet dogs treated at the same New Jersey, USA, small animal specialty veterinary hospital. The isolates were closely genetically related to the multistate cluster of Verona integron‐mediated metallo‐β‐lactamase (VIM)–producing and Guiana‐extended spectrum‐β‐lactamase (GES)–producing carbapenem‐resistant P. aeruginosa (VIM‐GES‐CRPA) isolated from multiple human clinical cultures and associated with contaminated over-the-counter artificial tears products (5,6). The combination of VIM-80 and GES-9 in a single organism had not been identified in the United States before that outbreak. By May 2023, that outbreak was associated with 81 human cases and 4 deaths in 18 states; no other animal cases were reported.

NJDOH interviewed the dog owners, reviewed veterinary medical and hospital purchase records, and conducted an onsite infection prevention and control (IPC) assessment 1 month after the second case identification. The investigation was reviewed by Centers for Disease Control and Prevention (CDC) and conducted consistent with federal law and CDC policy.

The first canine case was identified in March 2023 in a spayed female Labrador retriever 7 years of age that had a 3-month history of cough. VIM‐GES‐CRPA was isolated from a bronchoalveolar lavage specimen. The second canine case was identified in June 2023 in a neutered male cocker spaniel 6 years of age with a chronic history of otitis externa and keratoconjunctivitis sicca; VIM‐GES‐CP-PsA was isolated from the external ear canal along with methicillin-resistant Staphylococcus pseudintermedius. Clinical specimens were submitted to the clinical microbiology laboratory of the PennVet Diagnostic Laboratory, University of Pennsylvania (Philadelphia, PA, USA), for culture and antimicrobial susceptibility testing (AST).

AST was performed using AST-GN98 cards on Vitek 2 (bioMérieux, https://www.biomerieux.com), according to manufacturer instructions. Isolates tested were resistant to aminoglycosides amikacin and gentamicin, fluoroquinolones enrofloxacin and marbofloxacin, and ceftazidime. Isolate 13494-23 was resistant to imipenem. Although isolate 30793-23 was susceptible (MIC 2 μg/mL), ceftazidime resistance still prompted PCR by Carba-R (Cepheid, https://www.cepheid.com) for carbapenemase genes. Phenotypically susceptible isolates producing carbapenemases are a well-described phenomenon and prompt further investigation (7). Short-read whole-genome sequencing was performed using Nextera Library Prep chemistry and HiSeq 2500 (Illumina, https://www.illumina.com) platform and uploaded to National Center for Biotechnology Information (https://www.ncbi.nlm.nih.gov) prokaryotic genomic annotation pipeline for deposit in the pathogen detection database (8). The isolates were 2 and 5 single-nucleotide polymorphism differences from the closest related human isolate (Table).

Neither dog owners nor household members reported outbreak-associated ophthalmic product exposures since March 2022, but the second dog had received different over-the-counter artificial tears. The veterinary hospital did not stock the outbreak-associated products. Both dogs had received recent antimicrobial drug treatment. The first dog lived with 3 other dogs; the second dog was the only household pet. No dogs, owners, or household members had travel history (domestic or international) or healthcare setting exposures. Epidemiologic links between the 2 canine cases included treatment in the veterinary facility’s surgical preparation and recovery areas for both dogs and ophthalmology department visits by either the affected dog or another animal in the same household. The NJDOH onsite visit identified IPC gaps in hand hygiene, personal protective equipment use, and equipment and environmental cleaning and disinfection. Surgical scrub and instrument sink drains, shared equipment, and ophthalmic product cultures did not grow the outbreak strain. NJDOH provided IPC resources and recommendations to the facility and owners.

CPO identification in dogs linked to a human outbreak but with an unknown transmission route necessitates consideration of the role of companion animals and veterinary hospitals in transmitting and acting as reservoirs for CPOs and underscores the need for veterinary public health action. To clarify veterinary-associated CPO transmission and enhance CPO identification, veterinarians should request diagnostic laboratories perform carbapenem susceptibility testing for gram-negative bacteria resistant to third-generation cephalosporins (e.g., ceftazidime), if clinical history suggests CPO infection risk, and, upon carbapenem-resistant organism identification, request resistance mechanism confirmation. CPO infection risk can include recent antimicrobial use, international travel, hospitalization, raw food diet, close contact with humans or animals carrying CPOs, or exposure to contaminated products (9,10). Veterinarians and pet owners are encouraged to maintain awareness of outbreaks in persons associated with products used in multiple species, such as through Food and Drug Administration medical product recall notifications.

In conclusion, identifying CPOs in companion animals associated with a human outbreak serves as an urgent call to veterinarians to identify and prevent CPO transmission. Veterinarians should request carbapenem susceptibility testing when appropriate, veterinarians and pet owners should maintain awareness of CPO outbreaks, and veterinary hospitals should establish and implement IPC protocols. By following those recommendations, veterinarians can identify and prevent CPO transmission to protect animal and human health.

Dr. Price is a veterinary epidemiologist at the Centers for Disease Control and Prevention assigned to New Jersey Department of Health, Trenton, New Jersey, USA. Her research interests focus on healthcare associated infections and antimicrobial stewardship strategies in companion animals.

Top

Acknowledgment

We thank members of the veterinary facility for support with this investigation. We thank Maroya Walters, Danielle Rankin, Alison James, Kathy Benedict, and Sean Stapleton for their expertise and support during this investigation. We thank Jaclyn Dietrich for technical support.

Top

References

  1. Centers for Disease Control and Prevention. 2019 Antibiotic resistance threats report [cited 2023 Dec 6]. https://www.cdc.gov/antimicrobial-resistance/data-research/threats
  2. Hyun  JE, Chung  TH, Hwang  CY. Identification of VIM-2 metallo-β-lactamase-producing Pseudomonas aeruginosa isolated from dogs with pyoderma and otitis in Korea. Vet Dermatol. 2018;29:186e68. DOIPubMedGoogle Scholar
  3. Fernandes  MR, Sellera  FP, Moura  Q, Carvalho  MPN, Rosato  PN, Cerdeira  L, et al. Zooanthroponotic transmission of drug-resistant Pseudomonas aeruginosa, Brazil. Emerg Infect Dis. 2018;24:11602. DOIPubMedGoogle Scholar
  4. Wang  Y, Wang  X, Schwarz  S, Zhang  R, Lei  L, Liu  X, et al. IMP-45-producing multidrug-resistant Pseudomonas aeruginosa of canine origin. J Antimicrob Chemother. 2014;69:257981. DOIPubMedGoogle Scholar
  5. US Food and Drug Administration. FDA warns consumers not to purchase or use EzriCare Artificial Tears due to potential contamination [updated 8/25/2023] [cited 2023 Dec 6]. https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-consumers-not-purchase-or-use-ezricare-artificial-tears-due-potential-contamination
  6. Grossman  MK, Rankin  DA, Maloney  M, Stanton  RA, Gable  P, Stevens  VA, et al.; Multistate Pseudomonas Outbreak Investigation Group. Extensively drug-resistant Pseudomonas aeruginosa outbreak associated with artificial tears. Clin Infect Dis. 2024;79:614. DOIPubMedGoogle Scholar
  7. Livermore  DM, Andrews  JM, Hawkey  PM, Ho  PL, Keness  Y, Doi  Y, et al. Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly? J Antimicrob Chemother. 2012;67:156977. DOIPubMedGoogle Scholar
  8. Tatusova  T, DiCuccio  M, Badretdin  A, Chetvernin  V, Nawrocki  EP, Zaslavsky  L, et al. NCBI prokaryotic genome annotation pipeline. Nucleic Acids Res. 2016;44:661424. DOIPubMedGoogle Scholar
  9. Dazio  V, Nigg  A, Schmidt  JS, Brilhante  M, Mauri  N, Kuster  SP, et al. Acquisition and carriage of multidrug-resistant organisms in dogs and cats presented to small animal practices and clinics in Switzerland. J Vet Intern Med. 2021;35:9709. DOIPubMedGoogle Scholar
  10. van den Bunt  G, Fluit  AC, Spaninks  MP, Timmerman  AJ, Geurts  Y, Kant  A, et al. Faecal carriage, risk factors, acquisition and persistence of ESBL-producing Enterobacteriaceae in dogs and cats and co-carriage with humans belonging to the same household. J Antimicrob Chemother. 2020;75:34250. DOIPubMedGoogle Scholar

Top

Table

Top

Suggested citation for this article: Price ER, McDermott D, Sherman A, Kelley L, Mehr J, Greeley R, et al. Canine Pseudomonas aeruginosa cases linked to human artificial tears–related outbreak. Emerg Infect Dis. 2024 Dec [date cited]. https://doi.org/10.3201/eid3012.240085

DOI: 10.3201/eid3012.240085

Original Publication Date: November 20, 2024

Table of Contents – Volume 30, Number 12—December 2024

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.

Top

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Emma R. Price, New Jersey Department of Health, 135 E State St, Trenton, NJ 08625, USA

Send To

10000 character(s) remaining.

Top

Page created: November 20, 2024
Page updated: November 20, 2024
Page reviewed: November 20, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external